

Validation of AI-based software for objectification of conjunctival provocation test results in routine examinations and clinical studies

Yury Yarin^{1*}, Alexandra Kalaitzidi¹, Kira Bodrova¹, Ralf Mösges³, Yannis Kalaidzidis^{2*}

¹ Clinic for ENT and Allergology Dr. Yarin, 01139, Dresden, Germany

² Max Plank Institute for Molecular Cell Biology and Genetics, 01307, Dresden, Germany

³ ClinCompetence Cologne GmbH, 50668, Cologne, Germany

*Correspondence to Yury Yarin dr.yarin@gmail.com and Yannis Kalaidzidis kalaidzi@mpi-cbg.de

Key words: Allergy, Conjunctival Provocation Test, Deep Learning, AI

Abstracts:

1. Background:

Provocation tests are widely used in allergology to objectively reveal patients' sensitivity to specific allergens. The objective quantification of an allergic reaction is a crucial characteristic of these tests. Due to the absence of objective quantitative measurements the conjunctival provocation test (CPT) is a less frequently used method despite its sensitivity and simplicity. We developed a new method AllergoEye based on AI for quantitative evaluation of conjunctival allergic reactions and validated it in a clinical study.

2. Methods:

AllergoEye was implemented as a two component system. The first component is based on an Android smartphone camera for screening and imaging the patient's eye and the second one is PC based for image analysis and quantification. For the validation of AllergoEye an open-label, prospective, monocentric study was carried out on 41 patients. Standardized CPT was performed with sequential titration of grass allergens in 4 dilutions with the reaction evaluated by subjective/qualitative symptom scores and by quantitative AllergoEye scores.

3. Results:

AllergoEye demonstrated high sensitivity (98%) and specificity (90%) as compared with human-estimated allergic reaction. Tuning cut-off thresholds allowed to increase the specificity of AllergoEye to 97%, where the correlation between detected sensitivity to allergen and sIgE CAP-class becomes obvious. Strikingly, such correlation was not found with sensitivity to allergen detected by subjective and qualitative symptom scores.

4. Conclusion:

The clinical validation demonstrated that AllergoEye is a sensitive and efficient instrument for objective measurement of allergic reactions in CPT for clinical studies as well as for routine therapy control.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 1. Introduction

41
42 Provocation tests in allergology play an especially important role in the clinical cases of
43 patients with allergic symptoms who have negative skin reactions and negative Carrier-
44 Polymer-System (CAP) test results. The positive provocation reactions in this case are an
45 objective proof of allergy. On the other hand, negative results of provocation in patients with
46 positive skin tests and/or CAP without active allergic symptoms can reveal a sensitization
47 without clinical relevance. Therefore, with both positive and negative outcomes, provocation
48 tests support the decision on the necessity of therapy.

49
50 Among other provocation tests the conjunctival provocation test (CPT) is simpler than others
51 without compromising accuracy and sensitivity [1,2]. In the last years the CPT is used for
52 diagnosis as well as for therapy control and is becoming a crucial instrument of clinical
53 studies [3,4,5]. However, despite a hundred years of CPT history [6,3], its role is still limited
54 due to the main drawback - the subjective character of the evaluation of outcomes.
55 Nevertheless, the CPT has the same level of clinical importance as the nasal provocation test,
56 which includes an objective instrumental evaluation of outcomes [1,3,7]. Multiple clinical
57 studies demonstrated a high level of concordance between these two methods [8, 9, 10, 11].
58 Up to date the main method of evaluating the CPT is a summation symptom score (SSS) [2].
59 SSS is the sum of categorically (none (0), mild (1), moderate (2), severe (3), intolerable(4))
60 estimated symptoms, part of which are subjective patient estimation of allergy symptoms (like
61 eye itching, irritation and tearing) and eye redness subjectively estimated by medical staff
62 (observers) carrying out the test [3,11,6].

63
64 Modern evidence-based medicine requires quantitative reproducible evaluation of test results
65 for diagnostics as well as for assessments of the effectiveness of therapy carried out. To
66 overcome the CPT drawback, several approaches were proposed for the quantification of
67 CPT-outcomes [4, 12, 13, 14]. The readout of quantitative CPT methods is based on eye
68 redness measurement on digital images. The redness quantification can be divided into two
69 approaches. The first approach is based on the calculation of the apparent area of vessels in
70 the sclera [12, 15]. Therefore, vessels were 1) contrasted, 2) segmented and then the relative
71 area of sclera covered by segmented vessels was taken as a redness score. However, the
72 partial observation of the sclera and different eye ball orientation toward the camera on
73 sequential observations could degrade the accuracy of the method. Additionally, diffuse
74 redness, which is related to the widening of capillary that could not be resolved on non-

75 microscopic images, is not captured by this method. The second approach calculates the
76 redness for each pixel [4, 14]. The mean redness of the sclera [4] or histogram of redness
77 distribution [14] was then used as a redness score. In this case, one has to note, that there are
78 multiple definitions of redness [16, 4, 17] that could lead to different sensitivities of the
79 method. The crucial problem of per-pixel redness estimation is its dependency on the
80 reproducible color balance of the environment illumination and the automated white balance
81 of digital images. The limited application of all mentioned methods is either due to semi-
82 automated image analysis [4, 18, 12] or due to absence of automated correction for
83 illumination color changes (white balance) [14] or both of them [4, 18, 12, 14].

84 At the end of the last decade, the breakthrough in the Deep Learning approach brought
85 Artificial Intelligence methods into wide practice. In medicine it was applied in diagnostics,
86 image reconstruction in radiology modalities, emergency care devices etc. [19,20,21].
87 However, its usage in allergology is still limited. Recently we developed a new approach for
88 the qualitative evaluation of CPT results for diagnostics of allergic rhinoconjunctivitis and
89 implemented it in high-throughput software platform AllergoEye, which comprises of Deep
90 Neural Networks for automated image analysis and symptom evaluation [17]. For the
91 implementation of AllergoEye in broad clinical practice a validation study for quantitative
92 estimation of sensitivity and specificity of the method was required. In the presented work we
93 demonstrate the results of the clinical validation and efficiency of AllergoEye on a cohort of
94 patients with grass pollen allergy.

95
96

97 **2. Methods**

98
99

100 *2.1 Approvals and ethics*

101 The study was approved by the Ethics Committee (IEC) of the State Chamber of Physicians
102 of Saxony, Germany (IEC number EK-BR-111/21-1). The study was conducted in accordance
103 with local regulations, the International Conference on Harmonization of Technical
104 Requirements for Registration of Pharmaceuticals for Human Use (International Conference
105 on Harmonization (ICH)–Good Clinical Practices (GCP)) and the Declaration of Helsinki
106 [22].

107

108 2.2. Study design

109

110 This open-label, prospective, monocentric study was carried out in the Clinic of
111 Otorhinolaryngology and Allergology Dr. Yury Yarin (Dresden, Germany) in 2021. Female
112 and male patients between 18 and 75 years of age were included in this study. The study on
113 these grass pollen-allergic patients was performed outside of the grass pollen season and
114 consisted of 2 visits. Inclusion in the study took place after the patient signed the informed
115 consent prior to any study procedures being performed. For participation in the study the
116 patients were required to have a history of moderate or severe seasonal allergic
117 rhinoconjunctivitis (AR) with or without seasonal controlled asthma during the three grass
118 pollen seasons in the past. For objectivities of the allergy as criteria for the inclusion in a
119 study, a skin prick test and grass pollen-specific IgE (sIgE) antibodies were performed. A
120 wheal diameter ≥ 3 mm for a grass pollen allergen solution and sIgE antibodies > 0.01 kU/L
121 were the main necessary condition for study inclusion. Exclusion criteria were adapted from:
122 guidelines for daily practice [3] (see attachment 1).

123 During the first screening visit, the allergic anamneses was collected, the inclusion/exclusion
124 criteria were checked. After that the skin prick test was performed and a blood sample for the
125 antibody was taken. During the second visit, CPT was performed and estimated by summation
126 symptoms scores (SSS) [18] which were calculated at the end of the test by medical
127 personnel.

128 Simultaneously to the CPT procedure the results of patient's reactions on each applied
129 dilution were additionally recorded by AllergoEye. The results of the CPT and of AllergoEye
130 were joined into a merged database and statistical analysis was performed.

131

132 2.3. Titrated CPT Procedure

133 The CPTs and AllergoEye recording were conducted by the same investigator. Standardized
134 lyophilized allergen extracts for CPT with concentration in Histamine Equivalent Potency
135 units (HEP) 30 HEP/ml containing grass group supplied by Laboratorios LETI S.L. Madrid,
136 Spain were used. Reconstitution CPT stock solution was performed by drawing 4.8 mL from
137 a vial with 5.0 ± 0.2 mL of solvent and dispensing into a vial with grass extract. Further
138 dilution steps were 1:1000, 1:100, 1:10. A diluent will serve as negative control. The CPT was
139 performed by the following protocol: At the first step of the CPT, a negative control solution
140 (without allergens) is applied to the right eye. In case of a negative reaction after 5 minutes,
141 an allergen solution is applied stepwise to the left conjunctival sac in predefined increased
142 concentrations 1:1000, 1:100, 1:10 and stock solution. Between each application a 5 minutes
143 interval was held. The symptoms were documented in a standardized form [18] (see Table 1
144 in Suppl.Fig.3) in 5 minutes after allergen application. The four symptoms of tearing, itching,
145 irritations and redness were analyzed. Each of these symptoms was estimated and categorized

146 on a scale from 0 to 3, whereby, 0 = no reaction, 1 = mild reaction, 2 = moderate reaction, and
147 3 = strong reaction. Total score SSS was summarized from the meaning of all 4 symptoms
148 subjective (itching, irritation and tearing) and objective (redness evaluated by medical staff)
149 and built the value ranging from 0 to 12. The protocol was stopped when either medical
150 personnel detected redness of the treated eye or maximum allergen concentration was
151 achieved. Finally the allergen-provoked eye was treated with antihistaminic eye drops
152 (Ketotifen).

153

154 *2.4. AllergoEye - measurements and protocol*

155

156 During the CPT we described above, both patient's eyes were imaged 5 min after each
157 provocation, which was done on the left eye, with sequentially increased concentration of the
158 grass CPT solution. Control images were taken also before the test and after the treatment of
159 the right eye with a control solution (test solution without allergen). The eyes were imaged at
160 3 positions (looking straight forward, to the right and to the left) for maximum coverage of the
161 sclera. To control the illumination condition, the images were taken with a special mask (see
162 Figure 1A) with continuous white LED illumination. At the end of the test the images were
163 sent to a PC where the redness was evaluated by AllergoEye software.

164

165 *2.5. AllergoEye - technical description*

166

167 AllergoEye was implemented as a two component system. One part is based on an Android
168 smartphone HONOR 20 Pro (HUAWEI) and uses the build-in high-resolution photcamera
169 for imaging the patient eye's reaction to the allergen (Figure 1a). The second part is a PC
170 based software system, including the patient database, the communication module for
171 exchanging data with multiple smartphones and a deep neural network for image analysis and
172 redness evaluation. In short, patient's data and measurement details (allergen, dilution,
173 exposure time) are transferred from the PC to the mobile phone. The nurse acquires images of
174 two eyes and wirelessly transfers them to the PC. There, the deep neural network is used to
175 recognize and segment the iris and sclera. Additional control of coupling of iris and sclera as
176 well as the presence of two open eyes was performed to exclude segmentation artifacts. We
177 proposed a new method of per-pixel redness of sclera (R) evaluation as:

$$178 \quad R = \frac{27}{4} \left(r - \sqrt{\frac{g^2 + b^2}{2}} \right) \sqrt{r^2 + g^2 + b^2} \left(1 - \sqrt{r^2 + g^2 + b^2} \right)^2 \quad (1)$$

179 where r, g, b are normalized red, green and blue intensities respectively. The mean redness
180 and distribution of redness in the sclera are calculated for both treated and non-treated eyes

181 from all 3 eye positions. To take in account the inhomogeneity of the sclera reaction to the
182 allergen (see Figure 1b), the distribution of squared gradients of redness with 4 spatial steps
183 were calculated.

184 Despite of usage of a special mask (see Figure 1a), in some cases the changes of illumination
185 in the room during the examination led to the shift of white color balance of images (compare
186 right and left images on Figure 1b). To make our measurement robust to the illumination
187 change, we used the sclera of the untreated (right) eye as an internal control. For this end, the
188 redness distributions of both eyes were normalized (shifted) in such a way, that the redness
189 distribution of the right eye on test and control images had a maximum possible overlap. After
190 such normalization the difference between redness of the left eye in test and control
191 conditions were used as AllergoEye scores.

192 193 *2.6. Statistical Analysis*

194
195 For significance estimation the Student-t test was used. * denotes $p_{\text{value}} < 0.05$, ** denotes
196 $p_{\text{value}} < 0.01$, *** denotes $p_{\text{value}} < 0.001$. Statistical analysis and graph generation was
197 performed by model analysis software FitModel (<http://pluk.mpi-cbg.de/projects/fitmodel>).

198

199 3. Results

200

201 First we characterized the distribution of patients in the study (N=41) by eye sensitivity to the
202 grass allergen. As shown in Figure 2, most of the patients (n=16; 40%) exhibited a reaction at
203 allergen dilution 1:10, whereas only 4 (10%) were sensitive to dilution 1:1000. It was found
204 that 3 (8%) patients did not reveal any eye reaction for provocation at highest concentration
205 (stock solution) despite anamneses record of moderate to severe rhinoconjunctivitis.

206 Next we characterized AllergoEye's sensitivity/specificity. For this end we built a scatterplot
207 for 114 measurements (Figure 3a, blue points). Each point represents one measurement,
208 where the x-value is human-estimated redness score (from 0 to 3) and the y-value is an
209 AllergoEye score (from 0 to 3.7). Then we gradually changed the threshold value from 0 to
210 3.7, and for each threshold value we labeled the measurements as positive (above threshold)
211 or negative (below threshold). As the ground-truth labels we took human-assigned scores.
212 Therefore, a positive value was labelled as true-positive if it corresponds to human-assigned
213 non-zero score; otherwise it was labelled as false-positive. The true- and false-negative labels
214 were assigned in a similar way. From these labels we constructed a ROC-curve for
215 AllergoEye, where for each threshold value we calculated

$$216 \text{ Sensitivity} = \frac{\text{true-positive}}{\text{true-positive} + \text{false-negative}} \quad (2)$$

$$217 \text{ Specificity} = \frac{\text{true-positive}}{\text{true-positive} + \text{false-positive}} \quad (3)$$

218 The result is drawn as black dots on Figure 3b and presented in the table on Figure 3d. The
219 ROC-curve was smoothed (red line on Figure 3b) and the optimal threshold value was found
220 to be 0.3 as denoted by red dot on graph Figure 3b, highlighted on table Figure 3d and is
221 shown as a horizontal line on Figure 3a.

222 We found that 15 AllergoEye measurements were labelled as "false" at optimal threshold (red
223 and green bars on Figure 3a, Suppl. Fig.1). The human-estimated scores of these
224 measurements were re-evaluated by three independent experts. Re-evaluation changed
225 human-estimated scores in 9 cases (marked green in Suppl.Fig.1) while 6 were confirmed
226 (marked red in Suppl.Fig.1). In summary, AllergoEye was found to be more accurate than the
227 human operator (6 mistakes vs. 9 mistakes respectively). After re-evaluation a new ROC-
228 curve was build (Figure 3c,e). From table on Figure 3e, we found that AllergoEye sensitivity
229 towards eye redness is as high as 97.7% with 90% specificity.

230 Since usually an allergic reaction is estimated as the sum of subjective patient's symptoms
231 score and objective redness score [18] (SSS), we decided to compare the AllergoEye score
232 with SSS as a ground-truth. The scatter-plot of 114 measurements with SSS scores (from 0 to
233 12) on x-axis and AllergoEye score (from 0 to 3.7) on y-axis is drawn on Figure 4a by blue
234 dots. Similar to Figure 3a-c, the ROC-curve was plotted on Figure 4b, c. Interestingly, the
235 optimal threshold value was found to be the same (0.3) as in the redness only based ground-
236 truth. However, the sensitivity and specificity were lower (~87%) due to the presence of non-
237 redness related subjective symptoms scores.

238 In order to find the objectiveness of AllergoEye, we decided to compare the patient's
239 sensitivity as determined by the AllergoEye score with immunoglobulin sIgE concentration in
240 their blood. The sIgE concentration was scored in CAP-classes [23]. The characterization of
241 patients in the study by CAP-classes is shown on Figure 5a. Most of patients have CAP-class
242 3 and 4, however, 2 patients have CAP-class 6 and 2 patients have CAP-class 0 (sIgE is
243 slightly below the low boundary of CAP-class 1). We divided patients by sensitivity category
244 according to dilutions where the allergic reaction was detected according to criteria $SSS \geq 3$
245 or human-evaluated redness score > 1 . For each category, the mean CAP-classes were
246 calculated. In line with previous reports [24, 25], we did not find significant correlation
247 between mean CAP-classes and patient's allergic sensitivity as measured by SSS (Figure 5b).
248 Then we built graphs for mean CAP-classes vs. AllergoEye-evaluated allergy sensitivity for
249 the threshold value 0.3 (Figure 5c) and threshold value 0.5 (Figure 5d). Surprisingly, even
250 with AllergoEye threshold value 0.3 we found statistically significant difference between
251 CAP-classes of sensitive and insensitive patients (Figure 5c marked by stars). With
252 AllergoEye threshold value 0.5 (that corresponds to a specificity 97% to SSS, Figure 4c) we
253 revealed a statistically significant dependency between CAP-classes and patient's allergy
254 sensitivity (Figure 5d, marked by stars).

255

256 **4. Discussion**

257 Recent breakthrough in deep learning resulted in wide application of artificial intelligence
258 (AI) methods in engineering, science and medicine. Most successful AI applications were
259 achieved in the field of image analysis (e.g. radiology, diagnostics etc.). However, AI
260 application in allergology is rather limited.

261 The quantitative analysis of CPT in clinical practices is a long standing challenge in
262 allergology. We addressed this challenge by AI-based methods for image analysis and a new
263 method of eye redness evaluation. Up to date, most attempts to quantify the results of the CPT

264 were based on the quantitative analysis of eye reactions on allergen in the manually
265 segmented region of interest (ROI) in the sclera, either by measuring the apparent area of
266 vessels [4, 12] or by per-pixel redness evaluation [4, 14]. Although succeeding in clinical
267 studies, the methods based on manual ROI selection was too labor intensive for wide practices
268 and methods based on the apparent area of vessels was insensitive to the diffused redness
269 reaction of the sclera. Up to date, by best of our knowledge, only the work of Sirazitdinova
270 with co-authors was published where automated sclera segmentation was implemented (by
271 random forest method) [14]. However, similarly to previous works [4, 18, 12, 15] the method
272 of Sirazitdinova et al. [14] requires matching automatically selected key points on sclera
273 before and after provocation, which makes it too complicated for general practice usage.
274 Indeed, such matching requires an accurate repetitive eye ball orientation from the patient
275 during image acquisition, which significantly complicates the process of measurement and in
276 a case of operator carelessness could lead to a significant degradation of CPT quantification
277 accuracy.

278 Further, the measuring of the sclera redness is also impeded by the variation in illumination
279 and white balance in digital cameras. During the allergen titration time that can take tens of
280 minutes, the environment illumination conditions could change. Additional devices like a
281 facemask were very useful, but unfortunately do not allow to totally suppress the white
282 balance fluctuations. None of the previously proposed methods handle the changes in
283 environment illumination conditions in an automated manner [4, 12, 14, 15].

284 We developed a method that uses 1) a deep neuronal network (33 layers) for automated
285 segmentation of iris and sclera on the image, which exclude manual ROI selection and as such
286 increases the throughput of the method; 2) a new formula (1) for brightness-independent
287 redness per-pixel evaluation; 3) sclera redness score based on pixels redness distribution
288 which does not require keypoints matching before and after provocation; 4) an automated
289 white balance correction based on the untreated eye as an inner in-image control that makes
290 the method robust towards changes in environment illumination conditions. It is worth
291 repeating, that our method of allergic reaction evaluation is not based on widening
292 macroscopically recognizable vessels only, but also captures changes in a capillary network
293 that manifest itself in the diffuse redness of sclera.

294

295 The image processing and redness evaluation takes ~15 sec. on the PC (i7, Windows 10). In
296 rare cases, when the AI fails in an accurate segmentation of sclera, manual correction of ROI
297 with recalculation can be performed in a few seconds. The software stores subjective

298 symptoms and human-based redness evaluation of redness in the relational database. Cases
299 with contradiction between human-based redness evaluation and AllergoEye scores are easy
300 to find by database query and re-evaluate if it is necessary.

301 Nowadays, the gold standard of rating the results of CPTs is the so-called summation
302 symptom score (SSS), although there are more than one of score definitions that are used
303 today [18]. However, the SSS includes subjective feelings of patients and fails to reveal a
304 correlation with titer of sIgE as it was previously reported in literature [24, 25], where
305 correlation was found for very high sIgE titers and high SSS only. Such an absence of
306 correlation between CAP-classes and SSS was confirmed in our study (Figure 5b). One of
307 possible explanations of absence of the correlation between SSS and CAP-classes for middle
308 sensitive patients may be the personal ability to tolerate unpleasant feelings which differ
309 between patients that result in wide variation in subjective score values. Therefore, SSS based
310 methods only partially satisfy the requirement for evidence-based medicine, where especially
311 accurate numerical values are essential in clinical studies. In contrast, the AllergoEye scores
312 revealed an evident correlation between sIgE CAP-classes and patients' sensitivity to allergen
313 provocation (Figure 5d). Therefore, AllergoEye scores alone, as well as incorporated into SSS
314 [18], could provide an objective method for clinical studies and control therapy in general
315 allergological practice.

316 Validating diagnostic methods in medicine is an essential task in new developments. The
317 main objective of this study was the validation of the AllergoEye system by determining the
318 sensitivity and specificity curve, the so-called ROC curve, and the selection of optimal and
319 strict thresholds for allergic response evaluation. This validation was based on two
320 considerations. First, we compared the dilution of the CPT solution that triggered a reaction as
321 detected by the redness determined by medical staff vs. redness detected by AllergoEye
322 (Figure 3b,c). Second, we compared the dilution of the CPT solution that triggered reaction as
323 detected by the redness determined by SSS vs. redness detected by AllergoEye (Figure 4b).
324 Both comparisons showed a high sensitivity and specificity of AllergoEye (Figure 4b-d;
325 Figure 5 b,c) as an instrument for redness and allergy assessment. In addition, the superiority
326 of the AllergoEye over human and SSS estimation in terms of accuracy of obtained results in
327 terms of false positive and negative results was clearly demonstrated.

328 Selecting the right patients for the clinical trials in allergology overall and also using CPT is
329 an outstanding problem. The challenge is the large variability of the subjective symptoms of
330 CPT and absence of a clear correlation between these symptoms and objective parameters, in
331 particular the sIgE titer. Based on the AllergoEye ROC curves, the required specificity can be

332 chosen from tables presented in Figures 4 and 5. The strict specificity allows to objectively
333 select high sensitivity patients. At the same time the sensitivity value allows to estimate the
334 number of patients that have to be screened which is essential for clinical study design. In a
335 clinical trial AllergoEye could be used for quantitative monitoring of the efficiency of allergy
336 therapy, e.g. hyposensitization.

337
338 Thus, we presented a first fully automated AI based system for quantitative evaluation of CPT
339 results. Besides of allergology this platform could potentially be also applied for other
340 medical areas, e.g. ophthalmology, which is also accompanied by redness of the sclera.
341 Although this clinical validation of the method on patients with grass allergy was successful,
342 further studies are required on a larger cohort of patients for different types of seasonal and
343 perinatal allergies to demonstrate the universality of the AllergoEye method and its usefulness
344 for a wider range of routine examinations and clinical studies.

345

346 **5. Conclusion**

347 AllergoEye, an artificial intelligence-based platform for the quantification of conjunctival
348 provocation tests, showed high sensitivity and specificity compared to both the RMS, the
349 redness of eye as measured by medical personnel ($> 95\%$) and the SSS score, which
350 represents subjective patient reports ($> 86\%$). It showed a clear and statistically significant
351 correlation of the invoked allergic reaction in the eye with the IgE-CAP classes in the blood.
352 Clinical validation demonstrated that AllergoEye is a sensitive and efficient instrument for
353 objective evaluation of allergic reactions. It could be used for patient selection and controlling
354 the treatment efficiency in clinical studies as well as for diagnostic and therapy control in
355 routine allergological practice.

356

357 **6. Acknowledgments**

358 We thank Dr. Andreas Bilstein for useful discussions and help in preparing clinical study,
359 Laboratorios LETI S.L. Madrid for CPT reagents, and Alexander Kalaidzidis for software
360 development.

361 The authors declare no competing financial interests.

362 Author Contributions: Conceptualization Y.Yarin, Y.Kalaidzidis and Ralf Mösges; Clinical
363 study Y.Yarin and K. Bodrova; Documentation A.Kalaidzidi; Statistical analysis

364 Y.Kalaidzidis.

365

Literature

1. Hauswald, B and Yarin, YM, 2015. Moderne Diagnostik und Therapie der Rhinitis allergica [Modern Diagnosis and Therapy of the rhinitis allergica]. *Laryngorhinootologie*. May; 94(5):331- 345. German, DOI: <http://doi.org/10.1055/s-0035-1548900>.
2. Schröder, J and Mösges, R, 2018 Conjunctival provocation tests: prediction of seasonal allergy. *Oct*; 18(5):393-397, DOI: [10.1097/ACI.0000000000000470](https://doi.org/10.1097/ACI.0000000000000470).
3. Fauquert, JL, Jedrzejczak-Czechowicz, M, Rondon, C, Calder, V, Silva, D, Kvenshagen, BK, Callebaut, I, Allegri, P, Santos, N, Doan, S, Perez, Formigo, D, Chiambaretta, F, Delgado L and Leonardi, A, 2017. Interest Group on Ocular Allergy (IGOA) from the European Academy of Allergy and Clinical Immunology. Conjunctival allergen provocation test : guidelines for daily practice. *Jan*;72(1):43-54, DOI: [10.1111/all.12986](https://doi.org/10.1111/all.12986).
4. Sárándi, I, Claßen, DP, Astvatsatourov, A, Pfaar, O, Klimek, L, Mösges, R and Deserno, TM. 2014
Quantitative conjunctival provocation test for controlled clinical trials. *53(4):238-44*, DOI: [10.3414/ME13-12-0142](https://doi.org/10.3414/ME13-12-0142).
5. Ansoategui, IJ, Melioli, G, Canonica, GW, Caraballo, L, Villa, E, Ebisawa, M, Passalacqua, G, Savi, E, Ebo, D, Gómez, RM, Luengo, Sánchez, O, Oppenheimer, JJ, Jensen-Jarolim, E, Fischer, DA, Haahtela, T, Antila, M, Bousquet, JJ, Cardona, V, Chiang, WC, Demoly, PM, DuBuske, LM, Ferrer Puga, M, Gerth van Wijk, R, González Díaz, SN, Gonzalez-Estrada, A, Jares, E, Kalpaklioglu, AF, Kase Tanno, L, Kowalski, ML, Ledford, DK, Monge Ortega, OP, Morais-Almeida, M, Pfaar, O, Poulsen, LK, Pawankar, R, Renz, HE, Romano, AG, Rosário Filho, NA, Rosenwasser, L, Sánchez Borges, MA, Scala, E, Senna, GE, Sisul, JC, Tang, MLK, Yu-Hor, Thong, B, Valenta, R, Wood, RA and Zuberbier, T, 2021. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" *World Allergy Organ J*. Jun 17;14(7):100557, DOI: [10.1016/j.waojou.2021.100557](https://doi.org/10.1016/j.waojou.2021.100557).
6. Fineman A.H, 1926. Studies in hypersensitiveness. XXIII. A comparative study of the intradermal, scratch, and conjunctival tests in determining the degree of pollen sensitivity. *Journat of Immunotogy*, 11, 465. DOI:
7. Shamji, MH, Kappen, JH, Akdis, M, Jensen-Jarolim, E, Knol, EF, Kleine-Tebbe, J, Bohle, B, Chaker, AM, Till, SJ, Valenta, R, Poulsen, LK, Calderon, MA, Demoly, P, Pfaar, O, Jacobsen, L, Durham, SR and Schmidt-Weber, CB, 2017. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. *Allergy*. Aug;72(8):1156-1173, DOI: [10.1111/all.13138](https://doi.org/10.1111/all.13138).

8. Riechelmann, H, Epple, B and Gropper, G, 2003. Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Jan;130(1):51-9, DOI: 10.1159/000068369
9. Leonardi, A, Battista, MC, Gismondi, M, Fregona, IA and Secchi, AG, 1993. Antigen sensitivity evaluated by tear-specific and serum-specific IgE, skin tests, and conjunctival and nasal provocation tests in patients with ocular allergic disease. 17 (Pt 3):461-4. DOI:10.1038/eye.1993.93.
10. Mosbech, H, Dirksen, A, Madsen, F, Stahl, Skov P and Weeke, B, 1987. House dust mite asthma. Correlation between allergen sensitivity in various organs. Aug;42(6):456-63, DOI: 10.1111/j.1398-9995.1987.tb00363.x.
11. Petersson, G, Dreborg, S and Ingestad, R, 1986. Clinical history, skin prick test and RAST in the diagnosis of birch and timothy pollinosis. Aug;41(6):398-407, DOI: 10.1111/j.1398-9995.1986.tb00319.x.
12. Astvatsatourov, A and Mösges, R, 2015. Image-based assessment of allergic inflammation under conjunctival provocation. 213: 15–18. PMID: 26152941.
13. Horak, F, Berger, U, Menapace, R and Schuster, N, 1996. Quantification of conjunctival vascular reaction by digital imaging. Sep;98(3):495-500, DOI: 10.1016/s0091-6749(96)70081-7.
14. Sirazitdinov, E, Gijs, M, Bertens, CJF, Berendschot, TTJM, Nuijts, RMMA and Deserno, TM, 2019. Validation of Computerized Quantification of Ocular Redness. Dec 12;8(6):31. doi: 10.1167/tvst.8.6.31.
15. Dogan ,S, Astvatsatourov, A, Deserno, TM, Bock, F, Shah-Hosseini, K, Michels, A and Mösges, R, 2014. Objectifying the conjunctival provocation test: photography-based rating and digital analysis. 163(1):59-68, DOI: 10.1159/000355333.
16. Amparo, F, Wang, H, Emami-Naeini, P, Karimian, P and Dana, R, 2013. The Ocular Redness Index: a novel automated method for measuring ocular injection. Jul 18;54(7):4821-6, DOI: 10.1167/iovs.13-12217.
17. Yarin, Y, Kalaitzidou, A, Bodrova, K and Kalaitzidis, I, 2021. Die Effektivität von „AllergoEye“, eines vollautomatischen Systems basiert auf künstlicher Intelligenz, bei der Objektivierung des konjunktivalen Provokationstestes. Abstracts, 16. Deutscher Allergiekongress, Dresden, 30. September-2. Oktober 30(6): 61, DOI:10.1007/s15007-021-4862-1.

18. Pfaar, O, Claßen, DP, Astvatsatourov, A, Klimek, L and Mösges, R, 2018. Reliability of a New Symptom Score in a Titrated Quantitative Conjunctival Provocation Test Supported by an Objective Photodocumentation. 176:215-224, DOI: 10.1159/000487884.
19. Lee, JG, Jun, S, Cho, YW, Lee, H, Kim, GB, Seo, JB and Kim, N, 2017. Deep Learning in Medical Imaging: General Overview. Korean. Jul-Aug;18(4):570-584, DOI: 10.3348/kjr.2017.18.4.570.
20. Choi, J, Shin, K, Jung, J, Bae, HJ, Kim, DH, Byeon, JS and Kim, N, 2020. Convolutional Neural Network Technology in Endoscopic Imaging: Artificial Intelligence for Endoscopy. Mar;53(2):117-126, DOI: 10.5946/ce.2020.054.
21. Liu, PR, Lu, L, Zhang, JY, Huo, TT, Liu, SX and Ye, ZW, 2021. Application of Artificial Intelligence in Medicine: An Overview. Dec 6, DOI: 10.1007/s11596-021-2474-3.
22. World Medical Association, 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. 310:2191-2194. DOI: 10.1001/jama.2013.281053.
23. Kleine-Tebbe, J, Eickholt, M, Gätjen, M, Brunnée, T, O'Connor, A and Kunkel, G, 1992. Comparison between MAGIC LITE- and CAP-system: two automated specific IgE antibody assays. Apr;22(4):475-84, DOI: 10.1111/j.1365-2222.1992.tb00150.x.
24. Corsico, AG, De Amici, M, Ronzoni, V, Giunta, V, Mennitti, MC, Viscardi, A, Marseglia, GL and Ciprandi, G, 2017. Allergen-specific immunoglobulin E and allergic rhinitis severity. Mar 1;8(1):1-4, DOI: 10.2500/ar.2017.8.0187.
25. Lichtenstein, LM, Ishizaka, K, Norman, PS, Sobotka, AK, Hill and BM, 1973. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. Feb;52(2):472-82, DOI: 10.1172/JCI107204.

Legends

Figure 1. Workflow of PCT evaluation by AllergoEye. **A.** (left) Nurse makes image of patient's eyes by smartphone using AllergoEye mobile app (right), then image (top) is wireless transferred to PC-based AllergoEye application (bottom right), the result of analysis is transferred to mobile application for control. **B.** Sclera and iris are segmented by neural network (contoured in yellow). Sclera redness before (left image) and after (right image) provocation is shown.

Figure 2. Distribution of 41 patients by sensitivity defined as allergen dilution, where allergic reaction was detected as either $SSS \geq 3$. Left axis is number of patients; right axis is of percent patients.

Figure 3. A. Scatter plot of 114 measurements (blue dots), which were performed on 41 patients to reveal dependency between redness score estimated by medical staff (horizontal axis) and redness evaluated by AllergoEye (vertical axis). Horizontal cyan line denotes threshold equal 0.3 (see text). Red and green rectangles highlight measurements that “false negative” and “false positive” respectively. **B, D.** ROC curve (**B**) (Sensitivity vs. Specificity) as defined by threshold value gradually changing from 0.0 to 3.7 and its table presentation (**D**). Experimental data are presented by black dots; interpolation curve is drawn by red line. Optimal threshold (0.3) is marked by red dot. **C, E.** ROC curve and its table presentation similar to panels B and D, but measurements that are highlighted by red and green rectangles on panel A were re-evaluated by two independent observers and Redness score were corrected by majority voting (see Suppl. Figure 1). Sensitivity and specificity at optimal threshold are highlighted on panels **D** and **E** by cyan color.

Figure 4. A. Scatter plot of 114 measurements (blue dots), which were performed on 41 patients to reveal dependency between sum symptoms score (horizontal axis) and redness evaluated by AllergoEye (vertical axis). Horizontal cyan line denotes threshold equal 0.3. Red and green rectangles highlight measurements that “false negative” and “false positive” respectively. **B, C.** ROC curve (**B**) (Sensitivity vs. Specificity) as defined by threshold value gradually changing from 0.0 to 3.7 and its table presentation (**C**). Experimental data are presented by black dots; interpolation curve is drawn by red line. Optimal threshold (0.3) is marked by red dot. Sensitivity and specificity at optimal and stringent thresholds are highlighted on panels **C** by cyan color.

Figure 5. A. Distribution of 41 patients by sIgE CAP classes. Two patients although have CAP-class equal zero (sIgE was slightly below low boundary of CAP-class 1), but have clinically relevant symptoms. **B.** Mean CAP-class vs. sensitivity to allergen dilutions, as determined by SSS. **C.** Mean CAP-class vs. sensitivity to allergen dilutions, as determined by AllergoEye with cut-off threshold equal 0.3. **D.** Mean CAP-class vs. sensitivity to allergen dilutions, as determined by AllergoEye with cut-off threshold equal 0.5. Asterisks denote statistically significant differences, where * < 0.05; ** < 0.01; *** < 0.001.


Suppl. Figure 1. Table of re-evaluation of eye redness as defined by medial staff during CPT for the measurements highlighted on Figure 3A. The redness scores that were kept unchanged is highlighted by red, those that were changed after re-evaluation is highlighted by green. The re-evaluation was performed by 2 independent observers and final decision was done by majority votes.

Suppl. Figure 2. CAP-classes distribution among patients.

Suppl. Figure 3. Example of symptom score evaluation protocol.

Figure 1

A



B




Figure 2





Figure 3



D

E

Specificity (%)	Sensitivity (%)	AE-Score threshold	Specificity (%)	Sensitivity (%)	AE-Score threshold
0.00	100.00	0.00	0.00	100.00	0.00
60.82	100.00	0.10	74.65	100.00	0.15
75.68	95.00	0.20	76.06	100.00	0.20
82.35	96.70	0.25	86.00	98.50	0.25
85.32	95.00	0.30	90.14	97.67	0.30
91.18	87.20	0.35	93.07	83.72	0.35
93.10	84.20	0.40	94.37	78.80	0.40
94.60	77.50	0.45	95.77	76.74	0.45
95.90	75.00	0.50	97.18	74.42	0.50
98.70	70.00	0.75	99.90	65.00	0.75
100.00	57.50	1.00	100.00	53.20	1.00
100.00	35.00	2.00	100.00	32.50	2.00
100.00	10.00	3.00	100.00	9.30	3.00
100.00	1.50	3.70	100.00	2.30	3.70

Figure 4





Figure 5



Suppl. Fig.1

Gras 1-100	Redness was re-evaluated and found positive	TP
Gras 1-1 000	Redness was re-evaluated and found negative	FP
Gras 1-100	Redness was re-evaluated and found negative	FP
Gras 1-1 000	Redness was re-evaluated and found positive	TP
Gras 1-1 000	Redness was re-evaluated and found positive	TP
Gras 1-100	Redness was re-evaluated and found negative	TN
Gras 1-1 000	Redness was re-evaluated and found negative (red eye on start) (CAP-class =1)	FP
Gras 1-10	Redness was re-evaluated and found negative	TN
Gras 1-100	Redness was re-evaluated and found negative	TN
Gras 1-100	Redness was re-evaluated and found positive	TP
Gras 1-10	Redness was re-evaluated and found positive	FN
Gras Stocklösung	Redness was re-evaluated and found negative	TN
Gras 1-1 000	Redness was re-evaluated and found positive	TP
Gras 1-1 000	Redness was re-evaluated and found negative	FP
Gras 1-1 000	Redness was re-evaluated and found positive (CAP-class = 0)	FN

Suppl. Fig.2

	CAP Class						
	0	1	2	3	4	5	6
Male	1	1	3	8	10	1	1
Female	1	0	5	5	2	6	1

Suppl. Fig.3

Itching

- 0 = Not itchy
- 1 = Slightly itchy but not bothersome
- 2 = Itchy, bothersome and/or urge to rub eye at times
- 3 = Very itchy, very bothersome and/or urge to rub eye often

Irritation

- 0 = Not irritated
- 1 = Dry eye or other unusual feeling in eye, but not bothersome
- 2 = Gritty or foreign object feeling in eye, bothersome and/or urge to rub eye
- 3 = Burning or painful eye, very bothersome and/or difficulty keeping eye open and/or urge to rub eye often

Tearing

- 0 = Not watery
- 1 = Watery eye, but no tears and not bothersome
- 2 = Watery eye with a few tears, bothersome and/or urge to wipe eyes at times
- 3 = Watery eye with several tears, very bothersome and/or urge to wipe eye often

Redness

- 0 = No redness
 - 1 = Redness in conjunctiva bulbi
 - 2 = Redness in conjunctiva bulbi and tarsi
 - 3 = Redness in conjunctiva bulbi and tarsi and edema
-